Back to Journals » Hepatic Medicine: Evidence and Research » Volume 11

A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis

Authors Ganguli S, DeLeeuw P, Satapathy SK

Received 17 June 2019

Accepted for publication 3 October 2019

Published 15 November 2019 Volume 2019:11 Pages 159—178

DOI https://doi.org/10.2147/HMER.S188991

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Nicola Ludin

Peer reviewer comments 2

Editor who approved publication: Dr Gerry Lake-Bakaar


Surosree Ganguli,1 Peter DeLeeuw,2 Sanjaya K Satapathy3

1Division of Internal Medicine, University of Louisville, Louisville, KY 40202, USA; 2Division of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA; 3Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases, Northwell Health, Manhasset, NY 11030, USA

Correspondence: Sanjaya K Satapathy
Sandra Atlas Bass Center for Liver Diseases & Transplantation, Division of Hepatology, Department of Medicine, Northshore University Hospital/Northwell Health, 400 Community Drive, Manhasset, NY 11030, USA
Tel +1 516 562 0510
Fax +1 516 562 2688
Email ssatapat@northwell.edu

Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the West. Non-alcoholic steatohepatitis (NASH) is the progressive form of NAFLD and can lead to cirrhosis, hepatocellular carcinoma, and is associated with increased cardiovascular risks. Multiple components and risk factors are thought to be involved in the pathogenesis of NAFLD and NASH. Optimal therapy has not yet been found, but many advances have been made with the discovery of potential therapeutic options. In this paper, we aim to provide a comprehensive review of approved, studied, and upcoming treatment options for NAFLD and NASH. Non-pharmacologic therapy (lifestyle modifications and bariatric surgery) and pharmacologic therapy are both reviewed. Pharmacologic therapy target components thought to be involved in the pathogenesis of this disease process including insulin resistance, oxidative stress, inflammation, lipid metabolism, and fibrosis are reviewed in this paper. Results of the emerging treatment targets in phase 2 and 3 clinical trials are also included.

Keywords: NAFLD, NASH, obesity, cirrhosis, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]